

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 7970

**Title:** adjuvant Therapy for Pancreas Cancer: Past Lessons and Future Therapies

**Reviewer code:** 00503512

**Science editor:** Ma, Ya-Juan

**Date sent for review:** 2013-12-11 08:54

**Date reviewed:** 2013-12-12 08:28

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

In this paper, Sutton and Abbott review current options and future directions for PDAC Neoadjuvant Therapy. The review is well written and could benefit from a few minor changes: 1) In the molecular part, please clearly distinguish gene alterations and protein expression changes. Gene and protein symbols should be written in accordance to commonly accepted conventions: <http://www.xenbase.org/gene/static/geneNomenclature.jsp> 2) Among the new therapeutics and/or biomarkers, authors should at least mention something beyond classical protein-coding genes. Non coding RNAs and epigenetics play an increasingly important role in this field (see for example PMID: 22045191, 21652542, 22622284, 22614017) 3) in the conclusions, the authors should name the most promising therapies/molecular markers 4) Please eliminate typos: e.g. "approach approach"

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 7970

**Title:** adjuvant Therapy for Pancreas Cancer: Past Lessons and Future Therapies

**Reviewer code:** 02527475

**Science editor:** Ma, Ya-Juan

**Date sent for review:** 2013-12-11 08:54

**Date reviewed:** 2013-12-16 14:04

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

## COMMENTS TO AUTHORS

This is a well-written review of the pancreatic adenocarcinoma. The Table 2 and 3 were located on not the head of the page. The published years are missing in some of the references.

## ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 7970

**Title:** adjuvant Therapy for Pancreas Cancer: Past Lessons and Future Therapies

**Reviewer code:** 02098975

**Science editor:** Ma, Ya-Juan

**Date sent for review:** 2013-12-11 08:54

**Date reviewed:** 2013-12-18 08:14

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

This paper is a review of neoadjuvant therapy for pancreas cancer. Historical, currently wide spread, and future promising neoadjuvant therapy, besides adjuvant therapy, for pancreas cancer are well described based on the large number of references. In particular, the author highlights radiation therapy (chemoradiation), but the manuscript is slightly long and the mention is partly redundant. The following several sentences seems to be unnecessary from the viewpoint of the type of the review article. Page 5 lines 6 - 9 from the bottom; Due to criticisms regarding the randomization scheme, the relatively low-dose of radiation administered (a hypofractionated dose of 20Gy versus the traditional 50.4Gy), as well as the lack of quality control of the radiotherapy administered, the negative prognostic effect of chemoradiotherapy was generally not accepted within the United States. Page 17 lines 8 - 9 from the top; As radiation therapy is believed, by many, to decrease local recurrence, optimization of radiotherapy is a topic of great interest and research as well. Page 23 lines 1 - 3 from the bottom; To further investigate this, the multidisciplinary group at the University of Cincinnati is currently conducting an investigator-initiated trial of combination erlotinib and radiotherapy in the neoadjuvant setting for patients with locally advanced pancreatic cancer. Page 27 lines 1 -5 from the top; Though the heterogeneity of molecular markers within pancreatic cancer may provide an explanation for significant resistance and therapy failures, persistent development of novel therapeutic agents targeting these molecules may one day translate to improved patient survival. Ultimately, one can propose identification of an array of actionable biomarkers upon which a patient's optimized and individualized therapy can be tailored. Minor comments 1. Page 10 line 2 from the bottom: ACS-NSQIP should be spelled out at its first appearance in the paper. Probably, it is the same as the American College of Surgeons National Cancer Data Base in page 11 line 10 from



## **Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road,  
Wan Chai, Hong Kong, China

---

the top. 2. Page 12 line 6 from the bottom: The sentence “---, the median survival of those undergoing resection had not yet been reached, while ---” seems unfinished. Reached to what? For example, to statistical significance? 3. In references, about half of the references lack their published year.

**ESPS Peer-review Report**

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 7970

**Title:** adjuvant Therapy for Pancreas Cancer: Past Lessons and Future Therapies

**Reviewer code:** 00070310

**Science editor:** Ma, Ya-Juan

**Date sent for review:** 2013-12-11 08:54

**Date reviewed:** 2013-12-19 07:58

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

**COMMENTS TO AUTHORS**

This paper showed the review of neoadjuvant for pancreas cancer. This paper is interest, and well written and appropriate. It will be acceptable for publication except one. Please shorten this manuscript. I think that the part of 'Molecular markers of interest' is not necessary.